Please select the option that best describes you:
In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?
Are there data from trial patients who recurred, especially regarding what treatments they received?
Answer from: Medical Oncologist at Academic Institution
This would depend on when the patient recurred. If the patient recurred after completion of the dedicated time on A18 then I would consider re-investing in an IO combination. There really is no prospective data on this but current trials are allowing patients with prior IO to enroll in trials. ...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
Limited data in this clinical scenario. Per A18 (Lorusso et al., PMID 38521086), 32 patients received ICI as post-progression therapy, 25 of whom received Pembro. I am unable to find in the supplements whether those were patients from the placebo arm or from the pembro arm.I think if the patient rec...